Overview
VibrantX develops AI-driven macromolecule drugs.
Funding
Amounts as reported; USD estimates shown only when they matchListed 2 funding records. Latest funding: RMB 100M (Pre-Series A), Jan 13, 2022.
1 listed record lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 25, 2025 | Tens of millions of US dollars · Series A | Hongshan China, 三一创新投资, 杏泽资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Jan 13, 2022 | RMB 100M ≈ $14.3M · Pre-Series A | Hongshan China, 丹麓资本, 经纬创投 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 2 valuation records.
No chartable valuation estimates yet.
2 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Aug 25, 2025 | — · Series A | Hongshan China, 三一创新投资, 杏泽资本 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
| Jan 13, 2022 | — · Pre-Series A | Hongshan China, 丹麓资本, 经纬创投 | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
More Industry apps companies
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
AI驱动大分子药物研发商 信华生物是一家AI驱动大分子药物研发商